Medtronic said Monday that it was cleared to market a heart defibrillator implant that can be safely used in an MRI scanner.
Medtronic’s Evera SureScan is designated “MR conditional,” which means having an MRI with one is not known to pose a hazard to patients.
The device is implanted in a patient’s chest to treat dangerous rapid heartbeats. It is intended for patients at risk of sudden cardiac arrest. Medtronic said patients who have an Evera SureSycan device implanted in their bodies can receive MRI scans on any part of the body without positioning restrictions. The MR conditional designation only applies when Evera is used with a specific wire Medtronic developed.
The product will be available in September.
The powerful magnets in MRI machines can interfere with heart implants by making them speed up or making component turn or overheat, so safety regulators have long recommended that patients avoid MRI scans. Medtronic that is a problem because about one-third of ICD patients will need an MRI within four years of having the device implanted. The company said it has changed some software and hardware inside the titanium Evera implant to reduce those risks.
Medtronic and other companies have sold MRI-safe pacemakers for several years. However pacemakers are more common than ICDs, and Medtronic said developing an ICD was more complicated. Pacemakers are used to treat slow heartbeats and they deliver a steady stream of electrical pulses to keep a patient’s heart beating normally. ICDs are more complex: they contain pacemakers and additional systems that are used to sense irregular heartbeats and deliver electrical pulses or shocks to return the heart to a normal rhythm.
Dr. David Steinhaus, the head of Medtronic’s cardiac rhythm and heart failure business, said medical device companies are focusing on making their devices safe for use in MRI machines because the scans are becoming more common.
“With MRIs becoming way more prominent, becoming the preferred mode of imaging for certain kinds of disease … more and more device makers are concentrating on trying to make things that are MRI compatible,” he said.
Medtronic PLC said in May that a clinical trial showed MRI scans did not affect Evera’s ability to detect dangerous heart rhythms and respond to them.
Medtronic PLC had been based in Minnesota, but relocated to Ireland in January after it bought drug and medical device maker Covidien for $42.9 billion. Its shares fell $1.24 to $68.66 in afternoon trading.
